Global Markets
36.1% of patients on new Wegovy (NOVOB DC) weight-loss pill have no prior experience on a GLP-1 drug, new study finds; Among patients on new Wegovy pill, 21.1% switched from injectable wegovy, 15.8% switched from injectable zepbound
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
